Trends in Death Rates Among U.S. Adults With and Without Diabetes Between 1997 and 2006

Division of Diabetes Translation, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
Diabetes care (Impact Factor: 8.42). 06/2012; 35(6):1252-7. DOI: 10.2337/dc11-1162
Source: PubMed


To determine whether all-cause and cardiovascular disease (CVD) death rates declined between 1997 and 2006, a period of continued advances in treatment approaches and risk factor control, among U.S. adults with and without diabetes.
We compared 3-year death rates of four consecutive nationally representative samples (1997-1998, 1999-2000, 2001-2002, and 2003-2004) of U.S. adults aged 18 years and older using data from the National Health Interview Surveys linked to National Death Index.
Among diabetic adults, the CVD death rate declined by 40% (95% CI 23-54) and all-cause mortality declined by 23% (10-35) between the earliest and latest samples. There was no difference in the rates of decline in mortality between diabetic men and women. The excess CVD mortality rate associated with diabetes (i.e., compared with nondiabetic adults) decreased by 60% (from 5.8 to 2.3 CVD deaths per 1,000) while the excess all-cause mortality rate declined by 44% (from 10.8 to 6.1 deaths per 1,000).
Death rates among both U.S. men and women with diabetes declined substantially between 1997 and 2006, reducing the absolute difference between adults with and without diabetes. These encouraging findings, however, suggest that diabetes prevalence is likely to rise in the future if diabetes incidence is not curtailed.

99 Reads
  • Source
    • "Prediabetes currently affects more than 87 million US adults (38 %) and confers a lifetime risk of conversion to diabetes of 30–50 % [4, 5]. Insulin resistance syndromes (diabetes, prediabetes, and metabolic syndrome) are associated with up to 70 % of cardiovascular disease (CVD) cases, and adults with diabetes are twice as likely to die from heart disease and stroke than those without diabetes [3, 6, 7]. The American Diabetes Association (ADA) estimates the cost of managing diabetes for just 1 year to average $7,900 per patient. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Blood-based biomarker testing of insulin resistance (IR) and beta cell dysfunction may identify diabetes risk earlier than current glycemia-based approaches. This retrospective cohort study assessed 1,687 US patients at risk for cardiovascular disease (CVD) under routine clinical care with a comprehensive panel of 19 biomarkers and derived factors related to IR, beta cell function, and glycemic control. The mean age was 53 ± 15, 42 % were male, and 25 % had glycemic indicators consistent with prediabetes. An additional 45 % of the patients who had normal glycemic indicators were identified with IR or beta cell abnormalities. After 5.3 months of median follow-up, significantly more patients had improved than worsened their glycemic status in the prediabetic category (35 vs. 9 %; P < 0.0001) and in the “high normal” category (HbA1c values of 5.5–5.6; 56 vs. 18 %, p < 0.0001). Biomarker testing can identify IR early, enable and inform treatment, and improve glycemic control in a high proportion of patients. Electronic supplementary material The online version of this article (doi:10.1007/s12265-014-9577-1) contains supplementary material, which is available to authorized users.
    Journal of Cardiovascular Translational Research 07/2014; 7(6). DOI:10.1007/s12265-014-9577-1 · 3.02 Impact Factor
  • Source
    • "Despite decades of scientific endeavor, diabetes has remained a leading disease in the US that inflicts millions of patients.1 Moreover, chronic diabetes is believed to be the culprit for several other illnesses.2 "
    [Show abstract] [Hide abstract]
    ABSTRACT: Here, we investigated in diabetic mice the therapeutic effect of monocyte chemoattractant protein-1 (MCP-1), locally delivered by an electrospun scaffold, on transplanted islets. This therapeutic scheme is expected to exert a synergistic effect to ameliorate hyperglycemia and its associated nephrotic disorders. The cumulative amount of MCP-1 released from the scaffold in vitro within a 3-week window was 267.77±32.18 ng, without a compromise in bioactivity. After 8 weeks following the transplantation, the islet population stimulated by MCP-1 was 35.14%±7.23% larger than the non-stimulated islet population. Moreover, MCP-1 increased concentrations of blood insulin and C-peptide 2 by 49.83%±5.29% and 43.49%±9.21%, respectively. Consequently, the blood glucose concentration in the MCP-1 group was significantly lower than that in the control group at week 2 post-surgery. MCP-1 also enhanced the tolerance of sudden oral glucose challenge. The rapid decrease of blood creatinine, urine creatinine, and blood urea nitrogen suggested that the recovery of renal functions compromised by hyperglycemia could also be attributed to MCP-1. Our study shed new light on a synergistic strategy to alleviate hyperglycemia and nephrotic disorders in diabetic patients.
    International Journal of Nanomedicine 02/2014; 9(1):985-93. DOI:10.2147/IJN.S55812 · 4.38 Impact Factor
  • Source
    • "Intensive intervention with multiple drug combinations produces sustained beneficial effects with respect to vascular complications and mortality rates from any cause and cardiovascular causes, respectively [23]. A recent US report demonstrated that the mortality rates among both American men and women with diabetes decreased substantially between 1997 and 2006, reducing the absolute difference between adults with and without diabetes [24]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Although diabetes mellitus is an important risk factor of coronary artery disease (CAD), routine screening for CAD is not recommended for asymptomatic diabetic patients. We assessed the impact of chest pain on CAD risk according to the presence or absence of diabetes mellitus. We investigated the future CAD event rate in subjects with and without chest pain according to the presence or absence of diabetes in a prospective large-scale community-based study in Korea. Among 8,574 subjects (4,032 men and 4,542 women) without a history of CAD, 0.8% and 2.2% of non-diabetic and diabetic subjects, respectively, reported newly developed CAD events during 4 years of follow-up. Although the presence of chest pain at baseline was also significantly associated with an increased risk of CAD of more than 2-fold in both non-diabetic and diabetic subjects (P < 0.01), the risk of future CVD event in asymptomatic diabetic patients was not significantly different from that in non-diabetic subjects with chest pain (hazard ratio, 0.907; 95% confidence interval, 0.412 -- 1.998). The CAD event rate of asymptomatic subjects with diabetes was comparable to that of non-diabetic subjects reporting chest pain. Considering the high risk of CAD in asymptomatic diabetic patients, more clinical trials aimed at formulating strategies to screen asymptomatic diabetic subjects should be carried out.
    BMC Cardiovascular Disorders 10/2013; 13(1):87. DOI:10.1186/1471-2261-13-87 · 1.88 Impact Factor
Show more

Preview (2 Sources)

99 Reads
Available from